

TEVA PHARMACEUTICAL INDUSTRIES LTD  
Form 6-K  
February 17, 2009

**FORM 6-K**

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934**

For the month of February 2009

Commission File Number 0-16174



1

**Teva Pharmaceutical Industries Limited**

(Translation of registrant's name into English)

**5 Basel Street, P.O. Box 3190**

**Petach Tikva 49131 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  X

Form 40-F \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_\_

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes \_\_\_\_\_

No  X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b):  
82- \_\_\_\_\_



**Website: [www.tevapharm.com](http://www.tevapharm.com)**

Contact: Elana Holzman    Teva Pharmaceutical Industries Ltd.    972 (3) 926-7554  
              Kevin Mannix    Teva North America                                (215) 591-8912

**For Immediate Release**

TEVA INVITES PUBLIC TO LISTEN TO INVESTOR & ANALYST  
MEETING WEBCAST

Jerusalem, Israel, February 17, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast of its Investor & Analyst Meeting on Wednesday, February 18, 2009 at 4:30 p.m. ET.

What: Teva's Investor & Analyst Meeting

Who: Teva Management

When: Wednesday, February 18, 2009 at 4:30 p.m. ET

Where: [www.tevapharm.com](http://www.tevapharm.com) or

<http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=73925&eventID=2099215>

## Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 6-K

How: Live over the Internet -- log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

### About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.

Teva Pharmaceutical Industries Ltd.

Web Site: [www.tevapharm.com](http://www.tevapharm.com)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Registrant)

By: /s/ Eyal Desheh

Name: Eyal Desheh  
Title: Chief Financial Officer

Date: February 17, 2009



